vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and XPLR Infrastructure, LP (XIFR). Click either name above to swap in a different company.
XPLR Infrastructure, LP is the larger business by last-quarter revenue ($249.0M vs $183.1M, roughly 1.4× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 11.2%, a 2.1% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -15.3%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-88.0M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -1.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
XPLR Infrastructure is a publicly traded subsidiary of NextEra Energy, is a Juno Beach, Florida-based renewable energy company.
AMPH vs XIFR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $249.0M |
| Net Profit | $24.4M | $28.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -19.3% |
| Net Margin | 13.3% | 11.2% |
| Revenue YoY | -1.8% | -15.3% |
| Net Profit YoY | -35.7% | 124.3% |
| EPS (diluted) | $0.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $249.0M | ||
| Q3 25 | $191.8M | $315.0M | ||
| Q2 25 | $174.4M | $342.0M | ||
| Q1 25 | $170.5M | $282.0M | ||
| Q4 24 | $186.5M | $294.0M | ||
| Q3 24 | $191.2M | $319.0M | ||
| Q2 24 | $182.4M | $360.0M | ||
| Q1 24 | $171.8M | $257.0M |
| Q4 25 | $24.4M | $28.0M | ||
| Q3 25 | $17.4M | $-37.0M | ||
| Q2 25 | $31.0M | $79.0M | ||
| Q1 25 | $25.3M | $-98.0M | ||
| Q4 24 | $38.0M | $-115.0M | ||
| Q3 24 | $40.4M | $-40.0M | ||
| Q2 24 | $37.9M | $62.0M | ||
| Q1 24 | $43.2M | $70.0M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -19.3% | ||
| Q3 25 | 13.2% | 1.6% | ||
| Q2 25 | 24.2% | 26.3% | ||
| Q1 25 | 21.9% | -82.6% | ||
| Q4 24 | 24.2% | -188.1% | ||
| Q3 24 | 29.8% | 15.4% | ||
| Q2 24 | 30.3% | 18.3% | ||
| Q1 24 | 27.9% | -8.2% |
| Q4 25 | 13.3% | 11.2% | ||
| Q3 25 | 9.0% | -11.7% | ||
| Q2 25 | 17.8% | 23.1% | ||
| Q1 25 | 14.8% | -34.8% | ||
| Q4 24 | 20.4% | -39.1% | ||
| Q3 24 | 21.1% | -12.5% | ||
| Q2 24 | 20.8% | 17.2% | ||
| Q1 24 | 25.1% | 27.2% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $-0.40 | ||
| Q2 25 | $0.64 | $0.84 | ||
| Q1 25 | $0.51 | $-1.05 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $-0.43 | ||
| Q2 24 | $0.73 | $0.66 | ||
| Q1 24 | $0.81 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $960.0M |
| Total DebtLower is stronger | $608.7M | $6.2B |
| Stockholders' EquityBook value | $788.8M | $10.9B |
| Total Assets | $1.6B | $19.6B |
| Debt / EquityLower = less leverage | 0.77× | 0.57× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $960.0M | ||
| Q3 25 | $276.2M | $711.0M | ||
| Q2 25 | $231.8M | $880.0M | ||
| Q1 25 | $236.9M | $1.5B | ||
| Q4 24 | $221.6M | $283.0M | ||
| Q3 24 | $250.5M | $290.0M | ||
| Q2 24 | $217.8M | $281.0M | ||
| Q1 24 | $289.6M | $245.0M |
| Q4 25 | $608.7M | $6.2B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $5.3B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $10.9B | ||
| Q3 25 | $776.7M | $11.0B | ||
| Q2 25 | $757.5M | $11.3B | ||
| Q1 25 | $751.3M | $12.6B | ||
| Q4 24 | $732.3M | $12.9B | ||
| Q3 24 | $727.7M | $13.6B | ||
| Q2 24 | $713.3M | $13.9B | ||
| Q1 24 | $672.4M | $14.0B |
| Q4 25 | $1.6B | $19.6B | ||
| Q3 25 | $1.7B | $19.1B | ||
| Q2 25 | $1.6B | $20.5B | ||
| Q1 25 | $1.6B | $21.4B | ||
| Q4 24 | $1.6B | $20.3B | ||
| Q3 24 | $1.5B | $20.9B | ||
| Q2 24 | $1.5B | $21.7B | ||
| Q1 24 | $1.6B | $22.3B |
| Q4 25 | 0.77× | 0.57× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.41× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $186.0M |
| Free Cash FlowOCF − Capex | $24.6M | $-88.0M |
| FCF MarginFCF / Revenue | 13.4% | -35.3% |
| Capex IntensityCapex / Revenue | 4.5% | 110.0% |
| Cash ConversionOCF / Net Profit | 1.35× | 6.64× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-219.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $186.0M | ||
| Q3 25 | $52.6M | $231.0M | ||
| Q2 25 | $35.6M | $232.0M | ||
| Q1 25 | $35.1M | $90.0M | ||
| Q4 24 | $29.0M | $283.0M | ||
| Q3 24 | $60.0M | $208.0M | ||
| Q2 24 | $69.1M | $231.0M | ||
| Q1 24 | $55.3M | $78.0M |
| Q4 25 | $24.6M | $-88.0M | ||
| Q3 25 | $47.2M | $-283.0M | ||
| Q2 25 | $25.0M | $151.0M | ||
| Q1 25 | $24.4M | $1.0M | ||
| Q4 24 | $16.6M | $231.0M | ||
| Q3 24 | $46.2M | $152.0M | ||
| Q2 24 | $63.1M | $162.0M | ||
| Q1 24 | $46.5M | $14.0M |
| Q4 25 | 13.4% | -35.3% | ||
| Q3 25 | 24.6% | -89.8% | ||
| Q2 25 | 14.3% | 44.2% | ||
| Q1 25 | 14.3% | 0.4% | ||
| Q4 24 | 8.9% | 78.6% | ||
| Q3 24 | 24.1% | 47.6% | ||
| Q2 24 | 34.6% | 45.0% | ||
| Q1 24 | 27.1% | 5.4% |
| Q4 25 | 4.5% | 110.0% | ||
| Q3 25 | 2.8% | 163.2% | ||
| Q2 25 | 6.1% | 23.7% | ||
| Q1 25 | 6.3% | 31.6% | ||
| Q4 24 | 6.7% | 17.7% | ||
| Q3 24 | 7.2% | 17.6% | ||
| Q2 24 | 3.3% | 19.2% | ||
| Q1 24 | 5.1% | 24.9% |
| Q4 25 | 1.35× | 6.64× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 2.94× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 3.73× | ||
| Q1 24 | 1.28× | 1.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
XIFR
| Renewable Energy Sales | $238.0M | 96% |
| Related Party | $8.0M | 3% |
